Document:

Seventh  Amendment to Third Amended and Restated Credit Agmt, dated May 4, 2009.

 Exhibit 10.1 
 Execution Copy 
 SEVENTH AMENDMENT TO THIRD AMENDED 
 AND RESTATED CREDIT AGREEMENT 
 THIS
SEVENTH AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT (herein called this “Amendment”), dated effective as of May 4, 2009 (the “Effective Date”), is entered into by and among W&T
OFFSHORE, INC., a Texas corporation, as the borrower (the “Borrower”), the various financial institutions parties hereto, as lenders (collectively, the “Lenders”), TORONTO DOMINION (TEXAS) LLC,
individually and as agent (in such capacity together with any successors thereto, the “Agent”) for the Lenders, and the issuers of letters of credit parties hereto, as issuers (collectively, the “Issuers”). Terms
defined in the Credit Agreement (as hereinafter defined) are used herein with the same meanings as given them therein, unless the context otherwise requires. 
 W I T N E S S E T H 
 WHEREAS, the Borrower, the Lenders, the Agent and the Issuers have
heretofore executed that certain Third Amended and Restated Credit Agreement, dated as of May 26, 2006, as amended by that certain First Amendment to Third Amended and Restated Credit Agreement dated as of June 9, 2006, as further amended
by that certain Second Amendment to Third Amended and Restated Credit Agreement dated as of July 27, 2006, as further amended by that certain Third Amendment to Third Amended and Restated Credit Agreement dated as of June 7, 2007, as
further amended by that certain Waiver and Fourth Amendment to Third Amended and Restated Credit Agreement dated as of November 6, 2007, as further amended by that certain Fifth Amendment to Third Amended and Restated Credit Agreement dated as
of July 24 2008, and as further amended by that certain Sixth Amendment to Third Amended and Restated Credit Agreement dated as of December 18, 2008 (as so amended, and as from time to time amended, supplemented, restated or otherwise
modified prior to the date hereof, the “Credit Agreement”); and 
 WHEREAS, the parties hereto hereby further intend
to amend certain provisions of the Credit Agreement, in each case on the terms and conditions set forth herein. 
 NOW, THEREFORE, in
consideration of the premises and the mutual agreements herein contained, the undersigned hereby agree as follows: 
 1. Amendments to
Credit Agreement. The Credit Agreement is hereby amended as follows: 
 (a) Section 1.1. The following
definitions are hereby added to Section 1.1 of the Credit Agreement in the appropriate alphabetical order: 
 (i)
Section 1.1 of the Credit Agreement is hereby amended by adding the following definitions in the proper alphabetical order: 

 “Impacted Lender” means any Lender that (a) has not made available
to the Agent such Lender’s ratable portion of a requested borrowing or has not reimbursed an Issuer for such Lender’s ratable portion of the amount of a payment made by such Issuer under a Letter of Credit, in each case after the date due
therefor in accordance with the terms of the Credit Agreement, or has otherwise defaulted in its obligation to so fund or reimburse in accordance with the terms of the Credit Agreement; (b) has notified the Borrower or the Agent that it does
not intend to comply with its obligation to fund Loans or make reimbursements in respect of outstanding Letters of Credit under the Credit Agreement (and has not revoked such notice); or (c) is, or is a Subsidiary of a Person that is, the
subject of a bankruptcy, insolvency or similar proceeding. 
 “Reference Eurodollar Rate” means, as of any
day, a rate of interest per annum equal to the Eurodollar Rate (for a one-month Interest Period) on such day or, if such day is not a Business Day, the immediately preceding Business Day. 
 (ii) The definition of “Alternate Base Rate” in Section 1.1 of the Credit Agreement is hereby amended and restated
in its entirety as follows: 
 “Alternate Base Rate” means, for any day, the per annum rate equal to the
Base Rate Margin plus the highest of the determinable of (i) the Prime Rate, (ii) the Federal Funds Rate plus one-half percent (0.5%) per annum, and (iii) the Reference Eurodollar Rate plus one percent (1%) per annum. If
the Prime Rate or the Federal Funds Rate changes after the date hereof, the Alternate Base Rate shall be automatically increased or decreased, as the case may be, without notice to Borrower, from time to time as of the effective time of each such
change. The Alternate Base Rate shall in no event, however, exceed the Highest Lawful Rate. If for any reason the Agent shall have determined (which determination shall be conclusive and binding, absent manifest error) that it is unable to ascertain
the Federal Funds Rate for any reason, including, without limitation, the inability or failure of the Agent to obtain sufficient bids or publications in accordance with the terms hereof, the Alternate Base Rate shall be determined using the Prime
Rate until the circumstances giving rise to such inability no longer exist. 
 (iii) Clause (c) of the definition of
“Base Rate Margin” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows: 
 “(c) with respect to Revolving Loans, the applicable rate per annum equal to: 
 (i)
three-quarters of one percent (0.750%) per annum when the Facility Usage on such day is less than twenty-five percent (25%) of the Borrowing Base on such day, 

 (ii) one percent (1.000%) per annum when the Facility Usage on such day is greater
than or equal to twenty-five percent (25%) but less than fifty percent (50%) of the Borrowing Base on such day, 
 (iii) one and one-quarter percent (1.250%) per annum when the Facility Usage on such day is greater than or equal to fifty percent (50%) of the Borrowing Base on such day, but less than seventy-five percent (75%) of the
Borrowing Base on such day, 
 (iv) one and one-half percent (1.500%) per annum when the Facility Usage on such day is
greater than or equal to seventy-five percent (75%) of the Borrowing Base on such day, but less than ninety percent (90%) of the Borrowing Base on such day, and 
 (v) one and three-quarters percent (1.750%) per annum when the Facility Usage on such day is greater than or equal to ninety
percent (90%) of the Borrowing Base on such day.” 
 (iv) The definition of “Commitment Fee Rate”
in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows: 
 “Commitment
Fee Rate” means, on each day, a rate per annum equal to one-half of one percent (0.500%). 
 (v) Clause (c) of
the definition of “Eurodollar Margin” in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows: 
 “(c) with respect to Revolving Loans, the applicable rate per annum equal to: 
 (i) two percent (2.000%) per annum when the Facility Usage on such day is less than twenty-five percent (25%) of the Borrowing
Base on such day, 
 (ii) two and one-quarter percent (2.250%) per annum when the Facility Usage on such day is greater
than or equal to twenty-five percent (25%) but less than fifty percent (50%) of the Borrowing Base on such day, 
 (iii) two and one-half percent (2.500%) per annum when the Facility Usage on such day is greater than or equal to fifty percent (50%) of the Borrowing Base on such day, but less than seventy-five percent (75%) of the
Borrowing Base on such day, 

 (iv) two and three-quarters percent (2.750%) per annum when the Facility Usage on
such day is greater than or equal to seventy-five percent (75%) of the Borrowing Base on such day, but less than ninety percent (90%) of the Borrowing Base on such day, and 
 (v) three percent (3.000%) per annum when the Facility Usage on such day is greater than or equal to ninety percent (90%) of
the Borrowing Base on such day.” 
 (b) Section 2.4 of the Credit Agreement is hereby amended by deleting the first sentence
thereof and replacing it with the following: “Borrower shall use all Loans to refinance the Tranche B Term Loans, finance capital expenditures, and provide working capital for its operations and for other general business purposes,
including the acquisition of oil and gas properties and related assets.” 
 (c) Section 2.11. Section 2.11 of the
Credit Agreement is hereby amended by inserting the following new clause (j) at the end of such Section following clause (i) thereof: 
 “(j) Notwithstanding anything herein to the contrary, no Issuer shall be obligated to issue, renew or extend a Letter of Credit if any Lender is at such time an Impacted Lender hereunder, unless such Issuer has
entered into arrangements reasonably satisfactory to such Issuer with the Borrower or such Impacted Lender to eliminate such Issuer’s risk with respect to such Impacted Lender. If any Letter of Credit Outstandings exist at the time a Lender is
an Impacted Lender, the Borrower shall within one Business Day following notice by the Agent cash collateralize such Impacted Lender’s portion of such Letter of Credit Outstandings in a manner reasonably satisfactory to such Issuer for so long
as such Lender is an Impacted Lender and such Letter of Credit Outstandings exist.” 
 (d) Section 3.4. Section 3.4 of
the Credit Agreement is hereby amended by changing the words “Adjusted Eurodollar Rate” to “Eurodollar Rate”. 
 (e)
Section 7.5(c). Section 7.5(c) of the Credit Agreement is hereby amended by changing the words “the Borrower shall notify the Agent in writing” to “the Borrower shall notify the Agent in writing (including notice by
email)”. 
 (f) Section 7.12. Section 7.12 of the Credit Agreement is hereby amended and restated in its entirety as
follows: 
 “Section 7.12. Leverage Ratio. The Borrower will not permit its Leverage Ratio (a) as of
the last day of any Fiscal Quarter prior to and including the Fiscal Quarter ending June 30, 2009, to be greater than 3.00 to 1.00, (b) as of the last day of the Fiscal Quarter ending September 30, 2009, to be greater than 3.75 to
1.00, (c) as of the last day of the Fiscal Quarter ending December 31, 2009, to be greater than 3.50 to 1.00, (d) as of the last day of the Fiscal Quarter ending March 31, 2010, to be greater than 3.25 to 1.00 and (e) as of
the last day each Fiscal Quarter thereafter (commencing with the Fiscal Quarter ending June 30, 2010) to be greater than 3.00 to 1.00; provided that the calculation of the Borrower’s Leverage Ratio for purposes of this
Section 7.12 shall exclude any unrealized 

 
gains or losses or non-cash assets or liabilities in respect of Hedging Contracts described in, and calculated pursuant to, Statement of Financial Accounting
Standards 133 and 143, each as amended (provided that, for the avoidance of doubt, the calculation of Leverage Ratio shall include any gains, losses, assets or liabilities in respect of the termination of any Hedging Contracts).” 
 (g) The fifth sentence of Section 10.1(a) of the Credit Agreement is hereby amended by deleting the phrase “or (8) amend
Section 10.12” and inserting in lieu thereof the following: 
 “, (8) amend this sentence, (9) amend
Section 9.6 or (10) amend Section 10.12.” 
 2. Redetermination of Borrowing Base; Revolving Availability. The
Borrower and the Revolving Loan Lenders hereby agree that effective as of May 4, 2009, (a) the Borrowing Base shall be equal to $405,500,000 and (b) the Revolving Availability shall be equal to $405,500,000, in each case until such
time as the Borrowing Base and/or Revolving Availability are redetermined or otherwise adjusted pursuant to the terms of the Credit Agreement. 
 3. Representations and Warranties. The Borrower and each Restricted Person (if any) hereby represents and warrants that after giving effect hereto: 
 (a) the representations and warranties of the Borrower and such Restricted Person (if any) contained in the Loan Documents are true and
correct in all material respects on and as of the Effective Date, other than those representations and warranties that expressly relate solely to a specific earlier date, which shall remain correct in all material respects as of such earlier date;

 (b) the execution, delivery and performance by the Borrower and such Restricted Person (if any) of this Amendment are
within their corporate or limited liability powers, have been duly authorized by all necessary action, require, in respect of any of them, no action by or in respect of, or filing with, any governmental authority which has not been performed or
obtained and do not contravene, or constitute a default under, any provision of Law or regulation or the articles of incorporation or the bylaws of any of them or any agreement, judgment, injunction, order, decree or other instrument binding upon
the Borrower or such Restricted Person (if any) or result in the creation or imposition of any Lien on any asset of any of them except as contemplated by the Loan Documents; 
 (c) the execution, delivery and performance by the Borrower and such Restricted Person of this Amendment has been duly authorized by all
necessary action required on their part and this Amendment constitutes the legal, valid and binding obligation of each of them enforceable against them in accordance with its terms; and 
 (d) no Default or Event of Default has occurred and is continuing. 
 4. Effectiveness. This Amendment shall be deemed effective as of the Effective Date when (a) the Agent shall have received counterparts
hereof duly executed by the Borrower, the Agent and the Required Lenders, (b) the Agent shall have received for the account of each 

 
Lender that has delivered its executed counterpart this Amendment to the Agent (or otherwise provided to the Agent written evidence of its approval of the
amendments effectuated pursuant to Section 1 of this Amendment) on or prior to the Effective Date, an amendment fee for each such Lender in an amount equal to twenty-five (25) basis points on such Lender’s Aggregate Percentage Share
of the Borrowing Base and (c) the Borrower shall have repaid in full all outstanding Tranche B Term Loans. 
 5. Ratification;
Loan Document. This Amendment shall be deemed to be an amendment to the Credit Agreement, and the Credit Agreement, as hereby amended, is hereby ratified, approved and confirmed in each and every respect. The Borrower and each other Restricted
Person (if any) hereby ratifies, approves and confirms in every respect all the terms, provisions, conditions and obligations of the Loan Documents (including, without limitation, all Security Documents) to which it is a party. All references to the
Credit Agreement in any Loan Document or in any other document, instrument, agreement or writing shall hereafter be deemed to refer to the Credit Agreement as hereby amended. This Amendment is a Loan Document. 
 6. Costs And Expenses. As provided in Section 10.4 of the Credit Agreement, the Borrower agrees to reimburse Agent for all reasonable costs
and expenses incurred by or on behalf of Agent (including attorneys’ fees, consultants’ fees and engineering fees, travel costs and miscellaneous expenses) in connection with this Amendment and any other agreements, documents, instruments,
releases, terminations or other collateral instruments delivered by the Agent in connection with this Amendment. 
 7. GOVERNING
LAW. THIS AMENDMENT SHALL BE DEEMED A CONTRACT AND INSTRUMENT MADE UNDER THE LAWS OF THE STATE OF NEW YORK AND SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK AND THE LAWS OF THE UNITED
STATES OF AMERICA, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW. 
 8. Severability. Any provision of this Amendment that is
prohibited or unenforceable in any jurisdiction shall, as to such provision and such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Amendment or affecting the
validity or enforceability of such provision in any other jurisdiction. 
 9. Counterparts. This Amendment may be executed in any
number of counterparts, all of which taken together shall constitute one and the same instrument, and any party hereto may execute this Amendment by signing one or more counterparts. Any signature hereto delivered by a party by facsimile or
electronic transmission shall be deemed to be an original signature hereto. 
 10. Successors and Assigns. This Amendment shall be
binding upon the Borrower and its successors and permitted assigns and shall inure, together with all rights and remedies of each Lender Party hereunder, to the benefit of each Lender Party and its successors, transferees and assigns. 

 [The remainder of this page is intentionally left blank.] 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their
respective officers thereunto duly authorized as of the day and year first above written. 
  

			
	 BORROWER:
  
 W&T OFFSHORE, INC.

		
	By:	 	/s/ John D. Gibbons
	 Name:
 Title:
	 	 John D. Gibbons
 Chief Financial
Officer

  

			
	 TORONTO DOMINION (TEXAS) LLC,
 as Agent and
Lender

		
	By:	 	/s/ Ian Murray
	 Name:
 Title:
	 	 Ian Murray
 Authorized Signatory

  

			
	 THE TORONTO-DOMINION BANK,
 as
Issuer

		
	By:	 	/s/ Deborah Gravinese
	 Name:
 Title:
	 	 Deborah Gravinese
 Vice President

  
  

  

			
	 FORTIS CAPITAL CORP.
 as Issuer and Lender

		
	By:	 	/s/ David Montgomery
	 Name:
 Title:
	 	 David Montgomery
 Director

  

			
	
		
	By:	 	/s/ Darrell Holley
	 Name:
 Title:
	 	 Darrell Holley
 Managing Director

  
  

			
	 BMO CAPITAL MARKETS FINANCING, INC.,
 as
Lender

		
	By:	 	/s/ James V. Ducote
	 Name:
 Title:
	 	 James V. Ducote
 Director

			
	 BANK OF SCOTLAND,
 as
Lender

		
	By:	 	 
	Name: Title:	 	

			
	 NATIXIS,
 as Lender

		
	By:	 	/s/ Donovan C. Broussard
	 Name:
 Title:
	 	 Donovan C. Broussard
 Managing
Director

  

			
	
		
	By:	 	/s/ Liana Tchernysheva
	 Name:
 Title:
	 	 Liana Tchernysheva
 Director

			
	 GE BUSINESS FINANCIAL SERVICES, INC.
 f/k/a
MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC.,
 as Lender

		
	By:	 	 
	Name: Title:	 	

			
	 ROYAL BANK OF CANADA,
 as
Lender

		
	By:	 	 
	Name: Title:	 	

			
	 SOCIÉTÉ GÉNÉRALE,
 as Lender

		
	By:	 	 
	Name: Title:	 	

			
	 AMEGY BANK NATIONAL ASSOCIATION,
 as Lender

		
	By:	 	/s/ W. Bryan Chapman
	 Name:
 Title:
	 	 W. Bryan Chapman
 Senior Vice
President

			
	 BNP PARIBAS,
 as Lender

		
	By:	 	/s/ Betsy Jocher
	 Name:
 Title:
	 	 Betsy Jocher
 Director

  

			
	
		
	By:	 	/s/ Juan Carlos Sandoval
	 Name:
 Title:
	 	 Juan Carlos Sandoval
 Vice
President

			
	 GUARANTY BANK, FSB,
 as
Lender

		
	By:	 	/s/ Christopher S. Parada
	 Name:
 Title:
	 	 Christopher S. Parada
 Senior Vice
President

  

			
	 SUNTRUST BANK,
 as
Lender

		
	By:	 	 
	Name: Title:	 	

			
	 BANK OF AMERICA, N.A.,
 as
Lender

		
	By:	 	/s/ Jeffrey H. Rathkamp
	 Name:
 Title:
	 	 Jeffrey H. Rathkamp
 Managing
Director

			
	 ING CAPITAL LLC,
 as
Lender

		
	By:	 	/s/ Charles E. Han
	 Name:
 Title:
	 	 Charles E. Han
 Managing Director

  

			
	 MORGAN STANLEY BANK, N.A.,
 as
Lender

		
	By:	 	/s/ Melissa James
	 Name:
 Title:
	 	 Melissa James
 Authorized
Signatory

			
	 THE BANK OF NOVA SCOTIA,
 as
Lender

		
	By:	 	/s/ David G. Mills
	 Name:
 Title:
	 	 David G. Mills
 Managing DirectorCommercial Manufacturing Agreement

 Exhibit 10.66 
 *Portions of this document marked [*] are requested to be treated confidentially. 
 EXECUTION COPY 
 COMMERCIAL MANUFACTURING AGREEMENT 
 Salix Pharmaceuticals, Inc., Mesalamine Controlled Release Capsules 
 This Commercial
Manufacturing Agreement (“Agreement”) is made effective as of this 9th day of September, 2008 (“Effective Date”),
by and between Salix Pharmaceuticals, Inc., a California corporation, with a place of business at 1700 Perimeter Park Drive, Morrisville, NC, 27560 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company
with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”). 
 RECITALS 
 A.    Client is a pharmaceutical company that develops, markets and sells pharmaceutical products, including the Product; 

B.    Catalent provides contract pharmaceutical development, manufacturing, packaging and analytical services to the
pharmaceutical industry; 
 C.    Client desires to engage Catalent to provide certain services to Client in connection
with the processing of Client’s Product, and Catalent desires to provide such services, all pursuant to the terms and conditions set forth in this Agreement. 
 THEREFORE, in consideration of the mutual covenants, terms and conditions set forth below, the parties agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 The following terms have the following meanings in this Agreement: 
  

	1.1    “Acknowledgement”	has the meaning set forth in Section 4.3. 

 1.2    “Affiliate(s)” means, with respect to Client or any third party, any corporation, firm, partnership or other entity that controls, is controlled by or is under common control with such entity; and
with respect to Catalent, Catalent Pharma Solutions, Inc. (“CPS, Inc.”) and any corporation, firm, partnership or other entity controlled by CPS, Inc. For the purposes of this definition, “control” shall mean the
ownership of at least 50% of the voting share capital of an entity or any other comparable equity or ownership interest. 
 1.3    “Agreement” has the meaning set forth in the introductory paragraph, and includes all its Attachments and other appendices (all of which are incorporated herein by reference) and any amendments to
any of the foregoing made as provided herein or therein. 
 1.4    “API” means the compound 5-Amino Salicylic Acid, as
further described in the Specifications, as provided in this Agreement. 
 1.5    “API Inventions” has the meaning set
forth in Article 11. 

 EXECUTION COPY 
 1.6    “Applicable Laws” means all laws, ordinances, rules and regulations of the United States applicable to the Processing or any aspect thereof and the obligations of Catalent or Client, as the
context requires, under this Agreement, as amended from time to time, including (A) all applicable federal, state and local laws and regulations of the United States, (B) the U.S. Federal Food, Drug and Cosmetic Act and (C) cGMP.

 1.7    “Batch” means a defined quantity of Product that has been or is being Processed in accordance with the
Specifications. 
 1.8    “Catalent” has the meaning set forth in the introductory paragraph, or any successor or
permitted assign. Catalent shall have the right to cause any of its Affiliates to perform any of its obligations hereunder, and Client shall accept such performance as if it were performance by Catalent; provided that any Affiliate shall, at its
cost, comply with all Applicable Laws, including without limitation, the Regulatory Approval for the Product, unless Client requests the addition of the Affiliate to the Regulatory Approval. 
 1.9    “Catalent Indemnitees” has the meaning set forth in Section 13.2. 
 1.10    “Catalent IP” has the meaning set forth in Article 11. 
 1.11    “cGMP” means current Good Manufacturing Practices promulgated by the Regulatory Authorities, including within the meaning of 21 C.F.R. Parts 210 and 211, as amended.

 1.12    “Client” has the meaning set forth in the introductory paragraph, or any successor or permitted assign.

 1.13    “Client Indemnitees” has the meaning set forth in Section 13.1. 
 1.14    “Client IP” has the meaning set forth in Article 11. 
 1.15    “Client-supplied Materials” means any materials to be supplied by or on behalf of Client to Catalent for Processing, as provided in Attachment B, including API.

 1.16    “Commencement Date” means the first date upon which a Regulatory Authority approves Catalent as a
manufacturer of any Product. 
 1.17    “Confidential Information” has the meaning set forth in Section 10.2.

 1.18    “Contract Year” means, with respect to Contract Year 1, the period beginning on the Effective Date and ending
on December 31st of the first anniversary of the calendar year following the Commencement Date, and with respect to each Contract Year thereafter, each consecutive calendar year period beginning on January 1st and ending on
December 31st. 
 1.19    “Defective Product” has the meaning set forth in Section 5.1. 
 1.20    “Effective Date” has the meaning set forth in the introductory paragraph. 
 1.21    “Exception Notice” has the meaning set forth in Section 5.1. 
  

 2 

 EXECUTION COPY 
 1.22    “Facility” means Catalent’s facility located in Winchester, Kentucky, USA or such other facility as agreed in writing by the parties. 
 1.23    “Firm Commitment” has the meaning set forth in Section 4.2. 
 1.24    “Invention” has the meaning set forth in Article 11. 
 1.25    “Losses” has the meaning set forth in Section 13.1. 
 1.26    [*]. 
 1.27    “Process” or “Processing” means the
compounding, filling or pressing, producing and bulk packaging (but not secondary or retail packaging) of the API and Raw Materials into Product, in accordance with the Specifications and under the terms of this Agreement. 
 1.28    “Processing Date” means the day on which Product is scheduled to be compounded by Catalent, as identified in an
Acknowledgement in accordance with Section 4.3. 
 1.29    “Process Inventions” has the meaning set forth in
Article 11. 
 1.30    “Product” means the fully compounded bulk pharmaceutical product containing the API that has been
Processed in accordance with the Specifications. 
 1.31    “Product Maintenance Services” has the meaning set forth in
Section 2.3. 
 1.32    “Purchase Order” has the meaning set forth in Section 4.3. 
 1.33    “Quality Agreement” has the meaning set forth in Section 9.7. 
 1.34    “Raw Materials” means all raw materials, supplies, components and packaging necessary to manufacture and ship Product in
accordance with the Specifications, as provided in Attachment B, but not including Client-supplied Materials. 
 1.35    “Recall” has the meaning set forth in Section 9.6. 
 1.36    “Regulatory Approval” means any approvals, permits, product and/or establishment licenses, registrations or authorizations, including approvals pursuant to U.S. Investigational New Drug
applications, New Drug Applications and Abbreviated New Drug Applications, as applicable, of any Regulatory Authorities that are necessary or advisable in connection with the development, manufacture, testing, use, storage, exportation, importation,
transport, promotion, marketing, distribution or sale of Product in the Territory. 
 1.37    “Regulatory Authority”
means the international, federal, state or local governmental or regulatory bodies, agencies, departments, bureaus, courts or other entities in the United States (including the United States Food and Drug Administration) responsible for (A) the
regulation 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 3 

 EXECUTION COPY 
 (including pricing) of any aspect of pharmaceutical or medicinal products intended for human use or (B) health, safety or environmental matters generally. 
 1.38    “Review Period” has the meaning set forth in Section 5.1. 
 1.39    “Rolling Forecast” has the meaning set forth in Section 4.2. 
 1.40    “Specifications” means the procedures, requirements, standards, quality control testing and other data and the scope of services as set forth in Attachment B, along with any valid
amendments or modifications thereto, in accordance with Article 8. 
 1.41    “Supplier” has the meaning set forth in
Section 3.2(B). 
 1.42    “Term” has the meaning set forth in Section 16.1. 
 1.43    “Territory” means the United States of America, and any other country that the parties agree in writing to add to this
definition of Territory in an amendment to this Agreement. 
 1.44    “Unit Pricing” has the meaning set forth in
Section 7.1(B). 
 1.45    “Validation Services” has the meaning set forth in Section 2.1. 
 ARTICLE 2 
 VALIDATION,
PROCESSING & RELATED SERVICES 
 2.1    Validation Services. Catalent shall perform the qualification, validation and
stability services described in Attachment A (the “Validation Services”). Notwithstanding anything to the contrary in this Agreement, the Validation Services shall apply to Client’s [*] for Contract Year 1. 

2.2    Supply and Purchase of Product. Catalent shall Process Product in accordance with the Specifications, the Applicable Laws and the
terms and conditions of this Agreement. 
 2.3    Product Maintenance Services. Client will receive product maintenance services
(the “Product Maintenance Services”), [*], as applicable. In the event Client does not [*] pursuant to Section 4.1 herein. Catalent shall keep accurate records of any Product Maintenance Services utilized by
Client during a given Contract Year. Beginning at the end of Contract Year 2, either, party may request an annual review of the actual usage of Product Maintenance Services and Client shall be entitled to audit Catalent’s records regarding
Product Maintenance Services rendered to Client. Thereafter, the parties shall [*]. 
 2.4    Other Related Services.
Catalent, shall provide such Product-related services, other than Validation Services, Processing or Product Maintenance Services, as agreed to in writing by the parties from time to time. Such writing shall include the scope and fees for any such
services and 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 4 

 EXECUTION COPY 
 be appended to this Agreement. The terms and conditions of this Agreement shall govern and apply to such services. 
 ARTICLE 3

 MATERIALS 
 3.1    API. 
 A.     Client shall supply to Catalent for Processing, at Client’s
sole cost and risk, API, and any other Client-supplied Materials, in quantities sufficient to meet Client’s requirements for Product, as set forth in Article 4. Client shall deliver such items, together with associated certificates of analysis,
to the Facility no later than [*] days before, but not earlier than [*] months prior to, the Processing Date upon which such items will be used by Catalent. Client shall be responsible at its expense for securing any necessary export
or import clearances or permits required in respect of supply to Catalent of such items. Catalent shall use such items solely and exclusively for Processing of the Product. Prior to delivery of any such items, Client shall provide to Catalent a copy
of all associated material safety data sheets, and shall promptly provide any updates or revisions thereto. 
 B.    Within 30 days of receipt of API or any other Client-supplied Materials by Catalent, Catalent shall inspect such items to verify their identity and test such items to confirm that they meet the associated
specifications or certificate of analysis. In the event that Catalent detects a nonconformity with Specifications, Catalent shall give Client prompt oral and written notice of such nonconformity. Catalent shall not be liable for any defects in API
or any other Client-supplied Materials, or in Product as a result of defective API or any other Client-supplied Materials, unless Catalent failed to properly perform the foregoing obligations. Catalent shall follow Client’s reasonable written
instructions in respect of return or disposal of defective API or any other Client-supplied Materials, at Client’s sole cost and risk. 
 C.    Client shall retain title to API and any other Client-supplied Materials at all times and shall [*]. 
 3.2    Raw Materials. 
 A.    Catalent shall be responsible for sourcing and
qualifying third-party suppliers of Raw Materials. Catalent shall also be responsible for procuring, inspecting and releasing adequate Raw Materials as necessary to, meet the Firm Commitment, unless otherwise agreed to by the parties in writing.
Unless a particular Raw Material can be replaced with the same raw material from another supplier, Catalent shall not be liable for any delay in delivery of Product if (i) Catalent, exercising commercially reasonable efforts, is unable to
obtain, in a timely manner, a particular Raw Material necessary for Processing and (ii) Catalent placed orders for such Raw Materials promptly following receipt of Client’s Firm Commitment. In the event that any Raw Material becomes
subject to purchase lead time beyond the Firm Commitment time frame, the 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 5 

 EXECUTION COPY 
 parties will negotiate in good faith an appropriate amendment to this Agreement, including Sections 3.4 and 4.2. 
 B.    In certain instances, Client may require a specific supplier, manufacturer or vendor (“Supplier”) to be used for Raw Material. In such an event, (i) such Supplier will be identified in the
Specifications, (ii) Client shall be responsible for the timeliness, quantity, and quality of supply of Raw Materials from such Supplier, (iii) Catalent shall not be liable for any defects in Raw Materials from such Supplier, or in Product
as a result of such defective Raw Materials, unless Catalent failed to properly perform any testing required by the Specifications, and (iv) the Raw Materials from such Supplier shall be deemed, for purposes of liability hereunder,
Client-supplied Materials. If the cost of the Raw Material from any such Supplier is greater than Catalent’s costs for the same raw material of equal quality from other suppliers, Catalent shall notify Client in writing and provide Client with
documentary evidence of the same. If Client does not, within 20 business days of its receipt of such notice, designate a lower cost supplier identified in such notice, then Catalent shall [*]. If the documented cost of the Raw Material from
any supplier mandated by Client is less than Catalent’s documented cost for the same raw material of equal quality from other suppliers, then Catalent shall [*]. [*] will be responsible for all costs associated with qualification
of any such Supplier who has not been previously [*]. Catalent shall maintain an inventory of Raw Materials in sufficient quantities to be able to supply up to [*] per dose strength that is included in the Firm Commitment portion of
the most recent Client forecast. Notwithstanding anything to the contrary in this Section 3.2(B), a sole supplier of any Raw Material shall not be deemed a Supplier required by Client, nor shall the Raw Material supplied by such supplier be
deemed Client-supplied Materials. 
 3.3    Artwork and Packaging. Client shall provide or approve, prior to the procurement of
applicable components, all artwork, advertising and packaging information necessary for Processing, if any. Such artwork, advertising and packaging information is and shall remain the exclusive property of Client, and Client shall be solely
responsible for the content thereof. Such artwork, advertising and packaging information or any reproduction thereof may not be used by Catalent in any manner other than performing its obligations hereunder. 
 3.4    Reimbursement for Materials. In the event of (A) a Specification change for any reason, (B) obsolescence of any Raw Material
or (C) further to Section 16.3(C), termination or expiration of this Agreement, [*] shall bear the cost of any unused Raw Materials (including packaging), so long as [*]. 
 ARTICLE 4 
 [*], PURCHASE
ORDERS & FORECASTS 
 4.1    [*]. 
 4.2    Forecast. On or before the 15th day of each calendar month, beginning at least 90 days prior to the anticipated Commencement Date, Client shall furnish to Catalent a written [*] rolling 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 6 

 EXECUTION COPY 
 forecast of the quantities of Product that Client intends to order from Catalent during such period (“Rolling Forecast”). The first [*] months of such Rolling Forecast shall constitute a binding order for the
quantities of Product specified therein (“Firm Commitment”) and the following [*]; of the Rolling Forecast shall be non-binding, good faith estimates; provided however that Client shall be obligated to provide
purchase orders for the Firm commitment. If Client fails to timely provide a Rolling Forecast, the most recently provided Rolling Forecast shall be deemed resubmitted for the then-current [*]. 
 4.3    Purchase Orders. 
 A.    From time to time as provided in this Section 4.3(A), Client shall submit to Catalent a [*] purchase order for Product specifying the number of Batches to be Processed, the Batch size (to the extent the
Specifications permit Batches of different sizes) and the requested delivery date for each Batch (“Purchase Order”); provided, that no Purchase Order may be for less than [*]. Concurrently with the submission of each
Rolling Forecast, Client shall submit a Purchase Order for the Firm Commitment. Purchase Orders for quantities of Product in excess of the Firm Commitment shall be submitted by Client at least [*] days in advance of the delivery date
requested in the Purchase Order (“Lead Time Requirement”). Catalent shall be obligated to accept any Purchase Order that meets the Lead Time Requirement and that is for a quantity of Product that does not exceed [*] of the quantity
of Product set forth and agreed upon in the Firm Commitment. Catalent may reject Purchase Orders in excess of [*] more than the Firm Commitment. Failure to provide a Purchase Order does not absolve Client of its obligation regarding the Firm
Commitment. 
 B.    Catalent shall confirm in writing that a Purchase Order has been accepted within [*] business
days of receipt thereof by written acknowledgement (“Acknowledgement”) that it accepts or rejects such Purchase Order. Each Acknowledgement shall include the Processing Date and shall either confirm the delivery date set forth in
the Purchase Order or set forth a reasonable alternative delivery date; provided that any alternative delivery date proposed by Catalent is within [*] business days of the delivery date set forth in the Purchase Order. Catalent’s failure
to timely provide an Acknowledgement shall be deemed an acceptance of Client’s Purchase Order. 
 C.    Notwithstanding Section 4.3(A), Catalent shall use commercially reasonable efforts to supply Client with quantities of Product which are up to [*]% in excess of the quantities specified in the Firm
Commitment, subject to Catalent’s other supply commitments and manufacturing, packaging and equipment capacity; provided, that Catalent’s failure to supply Client with quantities in excess of the quantities specified in the Firm
Commitment shall not constitute a breach of this Agreement by Catalent. 
 D.    In the event of a conflict between the
terms of any Purchase Order or Acknowledgement and this Agreement, the terms of this Agreement shall control. 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 7 

 EXECUTION COPY 
 4.4    Postponement of Processing Date. Notwithstanding Section 4.5, Catalent reserves the right to postpone the Processing Date of all, or any part of, a Purchase Order upon written notice to Client, if
Client refuses or fails to timely supply conforming API or any other Client-supplied Materials in accordance with Section 3.1. In such event, Catalent shall exercise commercially reasonable efforts to reschedule the Processing Date within a
reasonable time and the parties shall negotiate in good faith a reasonable alternative delivery date for the Product subject to the affected Purchase Order. 
 4.5    Modification of Purchase Orders. An accepted Purchase Order may be modified only, by a written change order signed by both parties. Unless otherwise specifically agreed by the parties pursuant to a written
change order, both Client shall remain responsible for the Firm Commitment and Catalent shall Process the Product in accordance with the Firm Commitment. 
 4.6    Delivery. Catalent shall use commercially reasonable efforts to deliver in the quantity and on the shipment date specified for it on the Purchase Order, via the mode(s) of transportation and to the party
and destination specified on such Purchase Order. Catalent shall provide Client with as much advance notice as possible (and will use its best efforts to provide at least [*] days advance notice where possible) if Catalent determines that any
Processing will be delayed or eliminated for any reason. 
 4.7    Observation of Processing. In addition to Client’s audit
right pursuant to Section 9.5, Client may send up to [*] representatives to the Facility to observe Processing for a maximum of [*] days per Contract Year (unless otherwise agreed by Catalent in writing), so long as Client
provides Catalent at least [*] days’ advance written notice of the attendance of such Client representatives, including the name and title of each such representative. [*] shall be given access to Catalent’s Facility only
upon Catalent’s consent, which consent shall not be unreasonably withheld. Such representatives shall abide by all Catalent safety rules and other applicable employee policies and procedures, and Client shall be responsible for such compliance.
[*]. 
 4.8    Inability to Supply. If Catalent determines that it will not be able to supply Products to Client in
material satisfaction of the most recent Firm Commitment, Catalent shall promptly notify Client in writing of such determination, which notice shall provide Client with the details on the extent of the expected shortfall of supply, the causes of
such inability to supply, and Catalent’s proposed solution to the problem. Upon such notice of a supply problem, or in any event upon Catalent’s failure to timely deliver Product in accordance with Client’s Purchase Order,
(i) Client and Catalent will immediately meet and work together, in good faith, to identify an appropriate resolution to the supply problem, provided that Section 4.9 shall become applicable in the absence of any such resolution, and
(ii) Catalent shall, during any such shortfall of supply, use commercially reasonable efforts to continue to supply Products to Client. 
 4.9    Back-Up Trigger. In. the event that Catalent is unable for any reason to timely supply Client with Purchase Orders made in accordance with Article 4 other than for reasons attributable to Client’s
negligence, intentional wrongful actions, failure to supply API, or default 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 8 

 EXECUTION COPY 
 hereunder and such inability to supply lasts longer than [*] consecutive days, then in addition to, and without limitation of, any legal or equitable remedies available to Client as a result of any breach of this Supply Agreement by
Catalent, Client shall be free to engage a third party manufacturer for the Product or manufacture it directly upon written notice to Catalent, and Catalent shall reasonably cooperate with Client and such third party to effectuate the limited
transfer of Product from Catalent to Client or such third parry, as appropriate, to enable Client or the third party to manufacture Product; provided, however, that, during the Initial Term, upon receiving notice from Catalent that Catalent is in a
position to [*]. 
 ARTICLE 5 
 TESTING; SAMPLES; RELEASE 
 5.1    Testing; Releasing; Rejection. Within [*] days
after Catalent completes Processing of a Batch, Catalent shall provide Client or its designee with a certificate of analysis for such Batch. Client shall be responsible for final release of Product (including testing), at its cost. Following
Client’s receipt of a shipment of a Batch, Client or Client’s designee may test samples of such Batch to confirm that the Specifications have been met. Unless within [*] days after Client’s receipt of a Batch (“Review
Period”), Client or its designee notifies Catalent in writing (an “Exception Notice”) that such Batch does not meet the warranty set forth in Section 12.1 (“Defective Product”), the Batch shall be
deemed accepted by Client and Client shall have no right to reject such Batch. However, Client’s acceptance of a Batch shall not preclude a subsequent rejection of such Batch or any portion thereof following discovery of latent defects in such
Batch, including discovery of any substance that would cause Product to be adulterated within the meaning of the United States Food, Drug, and Cosmetic Act. Client must notify Catalent in writing within [*] days of discovery of a latent
defect, and such discovery shall not exceed [*] after Processing. Upon timely receipt of an Exception Notice from Client, Catalent shall conduct an appropriate investigation in its discretion to determine whether or not it agrees with Client
that Product is Defective Product and to determine the cause of any nonconformity. 
 If a shipment or partial shipment is rejected by Client pursuant to the
provisions of this Section 5.1, Client shall return to Catalent at Catalent’s request and expense (or, at the election of Client, destroy and provide evidence of such destruction to Catalent) any such rejected portion of the Batch.
Catalent shall (i) credit the original invoice and credit the amount, if any, paid by Client in respect of the rejected portion of the Batch (provided that if there are no additional Purchase Orders under this Agreement, the amount of the
credit shall be converted into a refund and Catalent shall refund such amount to Client) if Catalent agrees that the applicable portion of the Batch is non-conforming, and (ii) adjust the invoice to Client for any portion of the Batch that was
not rejected, payment of which is due in accordance with the terms of the original invoice. However, the provisions of this Section 5.1 are subject to Limitations of Liability contained in Article 14. 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 9 

 EXECUTION COPY 
 During the pendency of any rejection discussions Catalent shall, at Client’s request, use commercially reasonable efforts to promptly supply Client with additional Product, which Client shall purchase on the same terms as Product that
is the subject of the rejection discussions. 
 5.2    Discrepant Results. In the event of a disagreement between the parties
regarding whether Product is Defective Product, which disagreement cannot be resolved by the parties within [*] days of the date of the Exception Notice, the parties shall cause a mutually agreeable independent third party to review records,
test data and to perform comparative tests and/or analyses on samples of the alleged Defective Product and its components, including API and other Client-supplied Materials. The independent party’s results as to whether or not Product is
Defective Product and the cause of any nonconformity shall be final and binding. Unless otherwise agreed to by the parties in writing, the costs associated with such testing and review shall be borne by [*]. In the event the cause of
nonconformity cannot be determined or assigned, the costs associated with the Defective Product and the replacement of the same shall be shared equally between the parties. 
 5.3    Defective Processing. Catalent will, at Client’s option, either replace any Batch of Defective Product, or credit any payments made by Client for such rejected Batch. THE
OBLIGATION OF CATALENT TO REPLACE DEFECTIVE PRODUCT OR CREDIT PAYMENTS MADE BY CLIENT FOR DEFECTIVE PRODUCT SHALL BE [*]. 
 5.4    Supply of Material for Defective Product. In the event Catalent replaces Defective Product pursuant to Section 5.3, Client shall supply, at Catalent’s cost, subject to Section 14.1 herein,
Catalent with sufficient quantities of API, and other Client-supplied Materials in order for Catalent to complete such replacement Batch. 
 ARTICLE 6 
 DELIVERY 
 6.1    Delivery. Catalent shall segregate and store all Product until acceptance as set forth in Section 5.1. Catalent shall tender Product for delivery [*] the Facility promptly following
Catalent’s release of Product. [*] shall be responsible for all costs and risk of loss associated with shipment of the Product. Client shall designate a qualified carrier to Catalent. 
 6.2    Failure to Take Delivery. If Client fails to take delivery of any Product on any scheduled delivery date, Catalent shall store such
Product as Client’s agent, and [*]. For each such Batch of stored Product, Client agrees that: (A) [*], (B) [*], (C) [*], (D) [*], and (E) [*]. Within 5 days following a written
request from Catalent, Client shall provide Catalent with a letter confirming items (A) through (E) of this Section for each Batch of stored Product. 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 10 

 EXECUTION COPY 
 ARTICLE 7 
 PAYMENTS 
 7.1    Fees. In consideration for Catalent performing services hereunder: 
 (A)    Client shall pay to Catalent any unpaid fees for Validation Services set forth on Attachment A. Such fees shall be paid within [*] days following invoice, which invoice shall be submitted to Client
by Catalent upon the completion of the relevant phase of the Validation Services. 
 (B)    Client shall pay Catalent the
unit pricing for Product set forth on Attachment C (“Unit Pricing”). Such fees shall be paid within [*] days following invoice, which invoice shall be submitted to Client by Catalent upon tender of delivery of Product
as provided in Section 6.l. 
 (C)    Subject to Section 2.3, Client shall [*] set forth on
Attachment C. Such [*] shall be submitted to Client by Catalent upon the anniversary of each Contract Year during the Term. However, [*] will be [*]. 
 (C)    Other Fees. Client shall pay Catalent for all other fees and expenses of Catalent owing in accordance with the terms of
this Agreement, including pursuant to Sections 2.4, [*], [*] and 16.3. Such fees and expenses shall be paid within [*] days [*], which invoice shall be submitted to Client by Catalent as and when appropriate. 

7.2    Unit Pricing Adjustments. Beginning on January 1, [*], the Unit Pricing shall be subject to an [*] price
adjustment, effective on each anniversary date of the first [*] following the Effective Date. For any increases in Unit Pricing, the increase shall not exceed [*]. Catalent will provide Client with reasonable supporting documentation
for such increase at least ninety (90) days prior to a proposed price increase. Alternatively, for any decreases in Unit Pricing that may result from i) cooperative efforts between Catalent and Client relating to the manufacture of the Product,
ii) a decrease in the cost of labor or Raw Materials, or iii) Catalent experiencing a decrease in the cost of manufacture of the Product, Catalent shall notify Client and grant Client a reduction in Unit Pricing equal to at least [*] of the
related cost reduction. 
 7.3    Intentionally Omitted. 
 7.4    Payment Terms. Client shall make payment in U.S. dollars, and otherwise as directed in the applicable invoice. In the event payment on an undisputed invoice is not received by
Catalent on or before the [*] day after the [*], then Catalent may, in addition to any other remedies available at equity or in law, at its option, elect to do any one or more of the following: (A) [*]; (B) suspend any
further performance hereunder until such invoice is paid in full; and/or (C) terminate this Agreement pursuant to Section 16.2(B). For the avoidance of doubt, Catalent shall not be permitted to suspend performance or terminate the
Agreement, and [*] on any portion of an invoice disputed in good faith by Client. In the event Client disputes all or any portion of an 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 11 

 EXECUTION COPY 
 invoice, Client shall notify Catalent of the dispute within [*] days of Client’s receipt of the invoice, and the parties shall negotiate in good faith with respect to any disputed amount. 
 7.5    Taxes. All taxes, duties and other amounts assessed (excluding tax based on net income and franchise taxes) on services, components,
API or Product prior to or upon provision or sale to Catalent or Client, as the case may be, and on any other Client-supplied Materials, are the responsibility of Client, and Client shall reimburse Catalent for all such taxes, duties or other
expenses paid by Catalent or such sums will be added to invoices directed at Client, where applicable. 
 7.6.    Client and Third
Party Expenses. Except as may be expressly covered by Product Maintenance Service [*], Client shall be responsible for [*]% of its own and all third-party expenses associated with the development, Regulatory Approvals and
commercialization of Product, including regulatory filings and post-approval marketing studies. 
 7.7    Development Batches.
Each Batch produced under this Agreement, including those necessary to support the validation portion of Client’s submissions for Regulatory Approvals, will be considered to be a “development batch” unless and until Processing has
been validated. Client shall be responsible for the cost of each such Batch, even if such Batch fails to meet the Specifications, unless Catalent was grossly negligent in the manufacture of the out-of Specification Batch. Catalent and Client shall
cooperate in good faith to resolve any problems causing the out-of-Specification Batch. 
 ARTICLE 8 
 CHANGES TO SPECIFICATIONS 
 All Specifications and any
changes thereto agreed to by the parties from time to time shall be in writing, dated and signed by the parties. Any change to the Process requested in writing by Client shall be deemed a Specification change. No change in the Specifications shall
be implemented by Catalent, whether requested by Client or requested or required by any Regulatory Authority, until the parties have agreed in writing to such change, the implementation date of such change, and any increase or decrease in costs,
expenses or fees associated with such change (including any change to Unit Pricing). Catalent shall respond promptly to any request made by Client for a change in the Specifications, and both parties shall use commercially reasonable, good faith
efforts to agree to the terms of such change in a timely manner. As soon as possible after a request is made for any change in Specifications, Catalent shall notify Client of the costs associated with such change and shall provide such supporting
documentation as Client may reasonably require. Client shall pay all costs associated with such agreed upon changes as set forth in a written amendment to the Specifications signed by the parties. If there is a conflict between the terms of this
Agreement and the terms of the Specifications, this Agreement shall control. Catalent reserves the right to postpone effecting changes to the Specifications until such time as the parties agree to and execute the required written amendment.

  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 12 

 EXECUTION COPY 
 ARTICLE 9 
 RECORDS; REGULATORY MATTERS 
 9.1    Batch Records and Data. Within [*] days following the completion of Processing of each Batch, Catalent shall provide Client with
properly completed copies of Batch records prepared in accordance with the Specifications; provided, that if testing reveals an out-of-Specification result, Catalent shall provide such Batch records within [*] days following resolution
of the out-of Specification result. 
 9.2    Recordkeeping. Catalent shall maintain materially complete and accurate books,
records, test and laboratory data, reports and all other information relating to Processing, including all information required to be maintained by Applicable Laws, in accordance with Catalent standard operating procedures. Such information shall be
maintained in forms, notebooks and records for a period of at least [*] years from the relevant finished Product expiration date or longer if required under Applicable Laws. 
 9.3    Regulatory Compliance. Client shall be solely responsible for and will obtain all Regulatory Approvals, including any applications and amendments in connection therewith. Catalent
will be responsible to maintain all permits and licenses required by any Regulatory Authority with respect to the Facility generally, and for its performance of services hereunder. During the Term, Catalent will assist Client with all regulatory
matters relating to Processing, at Client’s request and at [*] expense. Each party intends and commits to cooperate to satisfy all Applicable Laws relating to Processing. 
 9.4    Governmental Inspections and Requests. Catalent shall promptly advise Client, and in any event within [*], if an authorized agent of any Regulatory Authority visits the
Facility concerning the Processing. Catalent shall furnish to Client a copy of the report by such Regulatory Authority, if any, within [*] business days of Catalent’s receipt of such report. Further, upon receipt of a Regulatory
Authority request to inspect the Facility or audit Catalent’s books and records with respect to Processing, Catalent shall notify Client within [*], and shall provide Client with a copy of any written document received from such
Regulatory Authority within [*] business days. 
 9.5    Client Inspections and Audits. 
 A.    During the Term, duly-authorized employees, agents and representatives of Client shall be granted access upon at least [*]
prior notice and at reasonable times during regular business hours to (i) the portion of the Facility where Catalent performs Processing, (ii) relevant personnel involved in Processing and (iii) Processing records described in
Section 9.2, in each case solely for the purpose of inspecting and verifying that Catalent is Processing in accordance with cGMPs, the Specifications and the Product master Batch records. Client shall provide the name and title of each such
employee, agent or representative to Catalent. Agents or independent contractors of Client shall be given access to Catalent’s Facility [*]. Client shall indemnify 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 13 

 EXECUTION COPY 
 Catalent for any and all acts or omissions of Client’s employees, agents, and representative while on Catalent’s premises. 
 B.    Client’s Quality Assurance Manager will arrange audit visits with Catalent Quality Management. Inspections shall be designed to minimize disruption of operations at the Facility. Client may not conduct an
inspection under this Section 9.5 more than [*] during any 12-month period; provided, that additional inspections may be conducted in the event there is a material quality or compliance issue concerning Product or its Processing.

 9.6    Recall. In the event Catalent believes a recall, field alert, Product withdrawal or field correction
(“Recall”) may be necessary with respect to any Product provided under this Agreement, Catalent shall immediately notify Client in writing. Catalent will not act to initiate a Recall without the express prior written approval of
Client, unless otherwise required by Applicable Laws. In the event Client believes a Recall may be necessary with respect to any Product provided under this Agreement, Client shall immediately notify Catalent in writing and Catalent shall provide
all necessary cooperation and assistance to Client. The cost of any Recall shall be borne by [*] and [*] shall reimburse [*] for expenses incurred with any Recall, in each case unless such Recall is caused solely by [*]
breach of its obligations under this Agreement or Applicable Laws or its negligence or willful misconduct, then such cost shall be borne by [*] and [*] shall reimburse [*] for expenses incurred with any Recall. For purposes
hereof, such cost shall be limited to reasonable, actual and documented administrative costs incurred by [*] for such Recall and replacement of the Product subject to Recall, in accordance with Article 5; provided, that NEITHER PARTY
SHALL BE LIABLE IN ANY EVENT FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES PROVIDED, HOWEVER, FOR PURPOSES OF CLARITY, THAT INDEMNIFIABLE LOSSES UNDER ARTICLE 13 SHALL NOT BE CHARACTERIZED AS INDIRECT, INCIDENTAL, SPECIAL OR
CONSEQUENTIAL TO CLIENT OR CATALENT SOLELY ON THE BASIS THAT SUCH LOSSES ARISE FROM SUCH DAMAGES SUFFERED BY THE THIRD PARTY. In the event that a Recall of Product, for which [*]. 
 9.7    Quality Agreement. Within [*] months after the Effective Date, the parties shall negotiate in good faith and enter into a Quality Agreement substantially in the form attached
hereto as Attachment D (the “Quality Agreement”). The Quality Agreement shall in no way determine liability or financial responsibility of the parties for the responsibilities set forth therein. In the event of a conflict
between any of the provisions of this Agreement and the Quality Agreement with respect to quality-related activities, including compliance with cGMP, the provisions of the Quality Agreement shall govern. In the event of a conflict between any of the
provisions of this Agreement and the Quality Agreement with respect to any commercial matters, including allocation of risk, liability and financial responsibility, the provisions of this Agreement shall govern. 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 14 

 EXECUTION COPY 
 ARTICLE 10 
 CONFIDENTIALITY AND NON-USE 
 10.1    Mutual Obligation. Catalent and Client each agrees that it will not use the other party’s Confidential Information except in
connection with the performance of its obligations hereunder and will not disclose the other parry’s Confidential Information to any third parry without the prior written consent of the other party, except as required by law, regulation or
court or administrative order; provided, that prior to making any such legally required disclosure, the party making such disclosure shall give the other party as much prior notice of the requirement for and contents of such disclosure as is
practicable under the circumstances. Notwithstanding the foregoing, each party may disclose the other party’s Confidential Information to any of its employees, representatives or Affiliates that (A) need to know such Confidential
Information for the purpose of performing under this Agreement, (B) are advised of the contents of this Article and (C) agree to be bound by the terms of this Article. 
 10.2    Definition. As used in this Agreement, the term “Confidential Information” includes all such information furnished by Catalent or Client, or any of their respective
representatives or Affiliates, to the other party or its representatives or Affiliates, whether furnished before, on or after the Effective Date and furnished in any form, including written, verbal, visual, electronic or in any other media or
manner. Confidential Information includes all proprietary technologies, know-how, trade secrets, discoveries, inventions and any other intellectual property (whether or not patented), analyses, compilations, business or technical information and
other materials prepared by either party, or any of their respective representatives or Affiliates, containing or based in whole or in part on any such information furnished by the other party or its representatives or Affiliates. Confidential
Information also includes the existence of this Agreement and its terms. 
 10.3    Exclusions. Notwithstanding Section 10.2,
Confidential Information does not include information that (A) is or becomes generally available to the public or within the industry to which such information relates other than as a result of a breach of this Agreement, (B) is already
known by the receiving party at the time of disclosure as evidenced by the receiving party’s written records, (C) becomes available to the receiving party on a non-confidential basis from a source that is entitled to disclose it on a
non-confidential basis or (D) was or is independently developed by or for the receiving party without reference to the Confidential Information of the other party as evidenced by the receiving party’s written records. 
 10.4    No Implied License. Except as expressly set forth in Section 10.1, the receiving party will obtain no right of any kind or
license under any Confidential Information of the disclosing party, including any patent application or patent, by reason of this Agreement. All Confidential Information will remain the sole property of the party disclosing such information or data,
subject to Article 11. 
 10.5    Return of Confidential Information. Upon expiration or termination of this Agreement, the party
receiving Confidential Information will cease its use and, upon request, within 30 days 

  

 15 

 EXECUTION COPY 
 either return or destroy (and certify as to such destruction) all Confidential Information of the other party, including any copies thereof, except for a single copy thereof which may be retained for the sole purpose of determining the
scope of the obligations incurred under this Agreement. 
 10.6    Survival. The obligations of this Article will terminate [*]
years from the expiration or termination of this Agreement, except with respect to trade secrets, for which the obligations of this Article will continue for so long as such information remains a trade secret under applicable law. 
 ARTICLE 11 
 INTELLECTUAL PROPERTY

 For purposes hereof, “Client IP” means all intellectual property and embodiments thereof owned by or licensed to Client as of the
date hereof or developed by Client other than in connection with this Agreement; “Catalent IP” means all intellectual property and embodiments thereof owned by or licensed to Catalent as of the date hereof or developed by Catalent
other than in connection with this Agreement; “Invention” means any intellectual property developed by either party in connection with this Agreement; “API Inventions” means any Invention that relates exclusively to
the Client IP or Client’s patented API; and “Process Inventions” means any Invention, other than an API Invention, that relates exclusively to the Catalent IP or relates to developing, formulating, manufacturing, filling,
processing, packaging, analyzing or testing pharmaceutical products generally. All Client IP and API Inventions shall be owned solely by Client and no right therein is granted to Catalent under this Agreement, except that Catalent shall have a
non-exclusive, royalty-free license to such items solely to the extent necessary to perform its obligations under this Agreement. All Catalent IP and Process Inventions shall be owned solely by Catalent and no right therein is granted to Client
under this Agreement. The parties shall cooperate to achieve the allocation of rights to Inventions anticipated herein and each party shall be solely responsible for costs associated with the protection of its intellectual property. 
 ARTICLE 12 
 REPRESENTATIONS AND
WARRANTIES 
 12.1    Catalent. Catalent represents, warrants and undertakes to Client that 
 A.    at the time of delivery by Catalent as provided in Section 6.1, Product shall have been Processed in accordance with
Applicable Laws and in conformance with the Specifications and shall not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws; provided, that Catalent shall not be liable for defects attributable to API or other
Client supplied Materials (including artwork, packaging and labeling); and 
 B.    it shall not a employ, contract with,
or retain any person directly or indirectly to perform any services under this Agreement if such person (a) is under investigation by the FDA for debarment or is presently debarred by the FDA pursuant to 21 U.S.C. § 335a or its successor

  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 16 

 EXECUTION COPY 
 provisions, or (b) has a disqualification hearing pending or has been disqualified by the FDA pursuant to 21 C.F.R. § 312.70 or its successor provisions, and it has not engaged in any conduct or activity that could lead to any of
the above-mentioned disqualification or debarment actions. If, during the Term, Catalent or any person employed or retained by it (i) comes under investigation by the FDA or other Governmental Authority for a debarment action or
disqualification, (ii) is debarred or disqualified, or (iii) engages in any conduct or activity that could lead to any of the above-mentioned disqualification or debarment actions, Catalent shall immediately notify Client of the same.

 12.2    Client. Client represents, warrants and undertakes to Catalent that: 
 A.    to the best of its knowledge, the API and all other Client-supplied Materials shall have been produced in accordance with
Applicable Laws, shall comply, with the Specifications, shall not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws, and shall have been provided in accordance with the terms and conditions of this Agreement; 

B.    to the best of its knowledge, no material safety data sheets are applicable to Product, API or any other Client-supplied
Materials, except as provided to Catalent in writing by Client in sufficient time for review and training by Catalent; 
 C.    all Product delivered to Client by Catalent will be held, used and disposed of by or on behalf of the Client in accordance with Applicable Laws, and Client will otherwise comply with all laws, rules, regulations
and guidelines applicable to Client’s performance under this Agreement and its use of Product provided by Catalent under this Agreement; 
 D.    Client will not release any Batch of Product if the required certificates of analysis indicate that Product does not comply with the Specifications; 
 E.    to its knowledge, Client has all necessary authority to use and to permit Catalent to use pursuant to this Agreement all
intellectual property related to Product, API, all other Client-supplied Materials (including artwork), and the Processing of the foregoing, including any copyrights, trademarks, trade secrets, patents, inventions and developments; 
 F.    the content of all artwork provided to Catalent shall comply with all Applicable Laws; and 
 G.    to its knowledge, the work to be performed by Catalent under this Agreement will not violate or infringe upon any trademark,
tradename, copyright, patent, trade secret, or other intellectual property or other right held by any person or entity. 
 12.3    Limitations. THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE BY EACH PARTY TO THE OTHER PARTY, AND NEITHER PARTY MAKES ANY OTHER
REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER, INCLUDING ANY IMPLIED WARRANTIES OF NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE. 
  

 17 

 EXECUTION COPY 
 ARTICLE 13 
 INDEMNIFICATION 
 13.1    Indemnification by Catalent. Catalent shall defend, indemnify and hold harmless Client, its Affiliates, and their respective directors, officers, employees and agents
(“Client Indemnitees”) from and against any and all suits, claims, losses, demands, liabilities, damages, costs and expenses (including reasonable attorneys’ fees and reasonable investigative costs) in connection with any suit,
demand or action by any third party (“Losses”) arising out of or resulting from (A) any breach of its representations, warranties or obligations set forth in this Agreement or (B) any negligence or willful misconduct by
Catalent or its Affiliates; in each case except to the extent that any of the foregoing arises out of or results from any Client Indemnitee’s negligence, willful misconduct or breach of this Agreement. 
 13.2    Indemnification by Client. Client shall defend, indemnify and hold harmless Catalent, its Affiliates, and their respective directors,
officers, employees and agents (“Catalent Indemnitees”) from and against any and all Losses arising out of or resulting from (A) any breach of its representations, warranties or obligations set forth in this Agreement,
(B) any manufacture, packaging, sale, promotion, distribution or use of or exposure to Product, API or any other Client-supplied Materials, including product liability or strict liability, (C) [*], (D) [*],
(E) [*], or (F) any negligence or willful misconduct by Client or its Affiliates; in each case except to the extent that any of the foregoing arises out of or results from any Catalent Indemnitee’s negligence, willful
misconduct or breach of this Agreement. 
 13.3    Indemnification Procedures. All indemnification obligations in this Agreement
are conditioned upon the party seeking indemnification (A) promptly notifying the indemnifying party of any claim or liability of which the party seeking indemnification becomes aware (including a copy of any related complaint, summons, notice
or other instrument); provided, that failure to provide such notice within a reasonable period of time shall not relieve the indemnifying party of any of its obligations hereunder except to the extent the indemnifying party is prejudiced by
such failure, (B) allowing the indemnifying party, if the indemnifying party so requests, to conduct and control the defense of any such claim or liability and any related settlement negotiations (at the indemnifying party’s expense),
(C) cooperating with the indemnifying party in the defense of any such claim or liability and any related settlement negotiations (at the indemnifying party’s expense) and (D) not compromising or settling any claim or liability
without prior written consent of the indemnifying party. 
 ARTICLE 14 
 LIMITATIONS OF LIABILITY 
 14.1    CATALENT’S LIABILITY UNDER THIS
AGREEMENT FOR ANY AND ALL CLAIMS FOR LOST, DAMAGED OR DESTROYED API OR OTHER CLIENT-SUPPLIED MATERIALS, WHETHER OR NOT SUCH API OR CLIENT-SUPPLIED MATERIALS ARE INCORPORATED INTO PRODUCT, SHALL NOT EXCEED [*]. 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 18 

 EXECUTION COPY 
 14.2    CATALENT’S TOTAL LIABILITY FOR [*] UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED $[*]. 
 14.3    EXCEPT AS SET FORTH IN SECTION 14.2 ABOVE, OR IN THE EVENT OF CATALENT’S [*], CATALENT’S TOTAL LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED $[*]. THE LIMITATION OF LIABILITY SET
FORTH IN THIS SECTION 14.3 SHALL NOT APPLY TO LOSSES OWING TO CLIENT UNDER SECTION 13.1, WITH RESPECT TO AMOUNTS PAID BY CLIENT TO THIRD PARTIES FOR BODILY INJURY. 
 14.4    NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES (PROVIDED, HOWEVER, FOR PURPOSES OF CLARITY, THAT INDEMNIFIABLE LOSSES UNDER ARTICLE 13 SHALL
NOT BE CHARACTERIZED AS INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL TO CLIENT OR CATALENT SOLELY ON THE BASIS THAT SUCH LOSSES ARISE FROM SUCH DAMAGES SUFFERED BY THE THIRD PARTY) OR LOSS OF REVENUES, REPUTATION, PROFITS OR DATA ARISING OUT OF
PERFORMANCE UNDER THIS AGREEMENT, WHETHER IN CONTRACT OR IN TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 
 ARTICLE 15 
 INSURANCE 
 15.1    Catalent Insurance. Catalent shall, at its own cost and expense, obtain and maintain in full force and effect the following insurance during the Term: (A) Commercial General Liability Insurance with a
per-occurrence limit of not less than an amount equivalent to $[*]; (B) Products and Completed Operations Liability Insurance with a per-occurrence limit of not less than an amount equivalent to $[*]; (C) Workers Compensation
and Employers Liability Insurance, with statutory limits for Workers Compensation and Employers Liability limits of not less than an amount equivalent to $[*] per accident; and (D) Professional Services Errors & Omissions
Liability Insurance with per-claim and aggregate limits of not less than an amount equivalent to $[*]. The parties hereby acknowledge and agree that Catalent may self-insure all or any portion of the required insurance. In the event that any
of the required policies of insurance are written on a claims made basis, then such policies shall be maintained during the entire Term and for a period of not less than [*] following the expiration or termination of this Agreement.
[*]. Catalent shall furnish to Client a certificate of insurance or other evidence of the required insurance [*] as soon as practicable after the Effective Date and within 30 days after renewal of such policies. Each insurance policy
which is required under this Agreement, other than self insurance, shall be obtained from an insurance carrier with an A.M. Best rating of at least A- VII. 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 19 

 EXECUTION COPY 
 15.2    Client Insurance. Client shall, at its own cost and expense, obtain and maintain in full force and effect the following insurance during the Term: (A) Commercial General Liability Insurance with a per
occurrence limit of not less than an amount equivalent to $[*]; (B) Products and Completed Operations Liability Insurance (including coverage for Product used in clinical trials) with a per occurrence limit of not less than an amount
equivalent to $[*]; (C) Workers Compensation and Employers Liability Insurance with statutory limits for Workers Compensation and Employers Liability limits of not less than an amount equivalent to $[*] per accident; and
(D) All Risk Property Insurance, [*], in an amount equal to [*]. The parties hereby acknowledge and agree that Client may self-insure all or any portion of the above-required insurance. Client shall maintain levels of insurance or
self insurance sufficient to meet its obligations under this Agreement. In the event that any of the required policies of insurance are written on a claims made basis, then such policies shall be maintained during the entire Term and for a period of
not less than [*] following the expiration or termination of this Agreement. [*]. Client shall furnish certificates of insurance evidencing the required insurance policies and [*] to Catalent as soon as practicable after the
Effective Date and within 30 days after renewal of such policies. Each insurance policy that is required under this Agreement shall be obtained, from an insurance carrier with an A.M. Best rating of at least A- VII. 
 ARTICLE 16 
 TERM AND TERMINATION

 16.1    Term. This Agreement shall commence on the Effective Date and shall continue until the end of the fifth Contract
Year, unless earlier terminated in accordance with Section 16.2 (as may be extended in accordance with this Section, the “Initial Term”). The Term shall automatically be extended for successive 3-year periods (each, a
“Renewal Term”), unless and until one party gives the other party at least 24 months’ prior written notice of its desire to terminate as of the end of the then-current Term (the Initial Term and any Renewal Terms are herein
collectively referred to as the “Term”). 
  

	16.2    Termination.	This Agreement may be terminated immediately without further action: 

 A.    by either party if the other party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the appointment of a receiver, administrative
receiver, trustee or administrator, or makes an assignment for the benefit of creditors, or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent and such order is not discharged within 30 days, or takes any
equivalent or similar action in consequence of debt in any jurisdiction; or 
 B.    by either party if the other party
materially breaches any of the provisions of this Agreement and such breach is not cured within 60 days after the giving of written notice requiring the breach to be remedied.; provided, that in the case of a failure of Client to make
undisputed payments in accordance with the terms of this Agreement, Catalent may terminate 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 20 

 EXECUTION COPY 
 this Agreement if such payment breach is not cured within 30 days of receipt of notice of nonpayment from Catalent. 
 C.    by either party for any reason or no reason upon 24 months prior written notice to the other party. 
 D.    by Client upon written notice to Catalent in the event of [*]. 
 16.3    Effect of
Termination. Expiration or termination of this Agreement shall be without prejudice to any rights or obligations that accrued to the benefit of either party prior to such expiration or termination. In the event of a termination of this
Agreement: 
 A.    Catalent shall promptly return to Client, at [*] expense and at Client’s direction, any
remaining inventory of Product, API or other Client-supplied Materials; provided, that Catalent shall have no obligation to so return such items until [*]; 
 B.    Client shall pay Catalent all invoiced amounts outstanding hereunder, [*]; and 
 C.    in the event that this Agreement is terminated for any reason other than by Client pursuant to Section 16.2(A) or (B) or by Catalent pursuant to Section 16.2(C), Client shall pay Catalent for
[*]. 
 16.4    Survival. The rights and obligations of the parties shall continue under Articles 11 (Intellectual
Property), 13 (Indemnification), 14 (Limitations of Liability), 17 (Notice), 18 (Miscellaneous); under Articles 10 (Confidentiality and Non-Use) and 15 (Insurance), in each case to the extent expressly stated therein; and under Sections 7.4 (Payment
Terms), 7.5 (Taxes), 7.6 (Client and Third Party Expenses), 9.2 (Recordkeeping), 9.6 (Recall), 12.3 (Limitations on Warranties), 16.3 (Effect of Termination) and 16.4 (Survival), in each case in accordance with their respective terms if applicable,
notwithstanding expiration or termination of this Agreement. 
 ARTICLE 17 
 NOTICE 
 All notices and other communications hereunder shall be in writing and shall be deemed
given: (A) when delivered personally; (B) when received or refused, if mailed by registered or certified mail (return receipt requested), postage prepaid; or (C) when delivered if sent by express courier service, to the parties at the
following addresses (or at such other address for a party as shall be specified by like notice; provided, that notices of a change of address shall be effective only upon receipt thereof): 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 21 

 EXECUTION COPY 
  

			
	 To Client:
	  	Salix Pharmaceuticals, Inc.
		  	1700 Perimeter Park Drive
		  	Morrisville, NC 27560
		  	USA
		  	 Attn: AVP, Pharmaceutical Development and
 Manufacturing

		
	 With a copy to:
	  	Salix Pharmaceuticals, Inc.
		  	1700 Perimeter Park Drive
		  	Morrisville, NC 27560
		  	USA
		  	Attn: General Counsel
		
	 To Catalent:
	  	Catalent Pharma Solutions, LLC
		  	1100 Enterprise Drive
		  	Winchester, KY 40391
		  	USA
		  	Attn: VP, General Manager
		  	Fax: 859-745-6636
		
	 With a copy to:
	  	Catalent Pharma Solutions, LLC
		  	14 Schoolhouse Road
		  	Somerset, NJ 08873
		  	USA
		  	Attn: General Counsel (Legal Department)
		  	Fax: 732-537-6491

 ARTICLE 18 
 MISCELLANEOUS 
 18.1    Entire Agreement; Amendments. This Agreement, together with the
Quality Agreement, as well as that certain Confidentiality Agreement dated June 1, 2004 between the parties, constitutes the entire understanding between the parties, and supersedes any contracts, agreements or understandings (oral or written)
of the parties, with respect to the subject matter hereof, including, for avoidance of doubt, that certain quotation letter (QTE-SAL.07.1207.00) dated December 7, 2007, and that certain quotation letter (QTE-SAL.09-2665.01). No term of this
Agreement may be amended except upon written agreement of both parties, unless otherwise expressly provided in this Agreement. 
 18.2    Captions; Certain Conventions. The captions in this Agreement are for convenience only and are not to be interpreted or construed as a substantive part of this Agreement. Unless otherwise expressly
provided herein or the context of this Agreement otherwise requires, (A). words of any gender include each other gender, (B) words such as “herein”, “hereof’, and “hereunder” refer to this Agreement as a whole and
not merely to the particular provision in which such words appear, (C) words using the singular shall include the plural, and vice versa, (D) the words “include(s)” and “including” shall be deemed to be followed by the
phrase “but 

  

 22 

 EXECUTION COPY 
 not limited to”, “without limitation” or words of similar import, (E) the word “or” shall be, deemed to include the word “and” (e.g., “and/or”) and (F) references to
“Article,” “Section,” “subsection,” “clause” or other subdivision, or to an Attachment or other appendix, without reference to a document are to the specified provision or Attachment of this Agreement. This
Agreement shall be construed as if it were drafted jointly by the parties. 
 18.3    Further Assurances. The parties agree to
execute, acknowledge and deliver such further instruments and to take all such other incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement. 
 18.4    No Waiver. Failure by either party to insist upon strict compliance with any term of this Agreement in any one or more instances will
not be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure. 
 18.5    Severability. If any term of this Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining terms of this Agreement will continue in full force and
effect. 
 18.6    Independent Contractors. The relationship of the parties is that of independent contractors, and neither party
will incur any debts or make any commitments for the other party except to the extent expressly provided in this Agreement. Nothing in this Agreement is intended to create or will be construed as creating between the parties the relationship of
joint ventures, co-partners, employer/employee or principal and agent. Neither party shall have any responsibility for the hiring, termination or compensation of the other party’s employees or contractors or for any employee benefits of any
such employee or contractor. 
 18.7    Successors and Assigns. This Agreement will be binding upon and inure to the benefit of
the parties, their successors and permitted assigns. Neither party may assign this Agreement, in whole or in part, without the prior written consent of the other party, except that either party may, without the other party’s consent, assign
this Agreement to an Affiliate or to a successor to substantially all of the business or assets of the assigning party or the assigning party’s business unit responsible for performance under this Agreement. 
 18.8    No Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the parties
named herein and their respective successors and permitted assigns. 
 18.9    Governing Law. This Agreement shall be governed by
and construed under the laws of the State of Delaware, USA excluding its conflicts of law provisions. 
 18.10    Alternative Dispute
Resolution. If any dispute arises between the parties in connection with this Agreement, such dispute shall be presented to the respective presidents or senior executives of Catalent and Client for their consideration and resolution. If such
parties cannot reach a resolution of the dispute, then such dispute shall be referred to non-binding mediation. If the parties are unable to resolve their dispute at mediation within 120 days following referral of such dispute, either party shall be
free to pursue any and all legal remedies available to such party. 
  

 23 

 EXECUTION COPY 
 18.11    Prevailing Party. In any dispute resolution proceeding between the parties in connection with this Agreement, the prevailing party will be entitled to recover its reasonable attorney’s fees and costs
in such proceeding from the other party. 
 18.12    Publicity. Neither party will make any press release or other public
disclosure regarding this Agreement or the transactions contemplated hereby without the other party’s express prior written consent, except as required under Applicable Laws, by any governmental agency or by the rules of any stock exchange on
which the securities of the disclosing party are listed, in which case the party required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the other party as to the form, nature and
extent of the press release or public disclosure prior to issuing the press release or making the public disclosure. 
 18.13    Force
Majeure. Except as to payments required under this Agreement, neither party shall be liable in damages for, nor shall this Agreement be terminable or cancelable by reason of, any delay or default in such party’s performance hereunder if
such default or delay is caused by events beyond such party’s reasonable control, including acts of God, law or regulation or other action or failure to act of any government or agency thereof, war or insurrection, civil commotion, destruction
of production facilities or materials by earthquake, fire, flood or weather, labor disturbances, epidemic or failure of suppliers, public utilities or common carriers; provided, that the party seeking relief under this Section shall
immediately notify the other party of such cause(s) beyond such party’s reasonable control. The party that may invoke this Section shall use commercially reasonable efforts to reinstate its ongoing obligations to the other party as soon as
practicable. If the cause(s) shall continue unabated for [*], then both parties shall meet to discuss and negotiate in good faith what modifications to this Agreement should result from such cause(s). 
 18.14    Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which
together will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall constitute an original. 
 [Signature page follows] 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC. 

  

 24 

 EXECUTION COPY 
 IN WITNESS WHEREOF, the parties have caused their respective duly authorized representatives to execute this Agreement effective as of the Effective Date. 
  

											
	 Catalent PharmaSolutions, LLC
	  	Salix Pharmaceuticals, Inc.	  	
						
	 By:
	 	 /s/    Ian Muir
	 		  	By:	  	  
	  	
						
	 Name:
	 	 Ian Muir
	 		  	Name:	  	  
	  	
						
	 Its:
	 	 VP Modified Release
	 		  	Its:	  	  
	  	

 EXECUTION COPY 
 IN WITNESS WHEREOF, the parties have caused their respective duly authorized representatives to execute this Agreement effective as of the Effective Date. 
  

											
	 Catalent Pharma Solutions, LLC
	  	Salix Pharmaceuticals, Inc.	  	
						
	 By:
	 	  
	 		  	By:	  	 /s/    William P. Forbes
	  	
						
	 Name:
	 	  
	 		  	Name:	  	 William P. Forbes
	  	
						
	 Its:
	 	  
	 		  	Its:	  	 VP, R&D and CDO
	  	

 EXECUTION COPY 
 ATTACHMENT A 
 VALIDATION SERVICES 
 See attached. 

 [*] 
  

	*	Confidential treatment requested; certain information omitted and filed separately with the SEC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]